They restrict access. The balance between clinical benefit, safety, and sustainability will be crucial.
Research agenda that follows:
Trials with more participants and clear inclusion criteria;
Multicenter collaborations and multi-year follow-up
; Protocols that minimize or eliminate immunosuppression;
Direct comparisons with artificial pancreas and other advanced therapies;
Outcome measures focused on quality of life and graft durability
Reported Results:
Chinese reports show a turning point in stem cell therapy for diabetes. Two patients discontinued insulin with stable control during the evaluation period. The clinical signal is encouraging and warrants attention. It also calls for caution. Extensive evidence is needed, as well as evidence of immune protection without aggressive drugs and confirmation of long-term safety. The promise is there. Validation is still underway.
